1-15 of 15
Jan H. Beumer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Project Confirm: Accelerated Drug Approvals for CML—Letter

Jan H. Beumer, Salvatore J. Salamone
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 235–236.
https://doi.org/10.1158/1078-0432.CCR-23-2630
Published: 05 January 2024
View article titled, Project Confirm: Accelerated Drug Approvals for CML—Letter
Open the PDF for Project Confirm: Accelerated Drug Approvals for CML—Letter in another window
Journal Articles

Precision Dosing of Targeted Therapies Is Ready for Prime Time

Stefanie L. Groenland, Remy B. Verheijen, Markus Joerger, Ron H.J. Mathijssen, Alex Sparreboom, Jos H. Beijnen, Jan H. Beumer, Neeltje Steeghs, Alwin D.R. Huitema
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6644–6652.
https://doi.org/10.1158/1078-0432.CCR-20-4555
Published: 15 December 2021
View article titled, Precision Dosing of Targeted Therapies Is Ready for Prime Time
Open the PDF for Precision Dosing of Targeted Therapies Is Ready for Prime Time in another window
Journal Articles

Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Samuel A. Jacobs, James J. Lee, Thomas J. George, James L. Wade, III, Philip J. Stella, Ding Wang, Ashwin R. Sama, Fanny Piette, Katherine L. Pogue-Geile, Rim S. Kim, Patrick G. Gavin, Corey Lipchik, Huichen Feng, Ying Wang, Melanie Finnigan, Brian F. Kiesel, Jan H. Beumer, Norman Wolmark, Peter C. Lucas, Carmen J. Allegra, Ashok Srinivasan
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1612–1622.
https://doi.org/10.1158/1078-0432.CCR-20-1831
Published: 15 March 2021
View article titled, Neratinib-Plus-Cetuximab in Quadruple-WT (<em>KRAS, NRAS, BRAF, PIK3CA</em>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Open the PDF for Neratinib-Plus-Cetuximab in Quadruple-WT (<em>KRAS, NRAS, BRAF, PIK3CA</em>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma

Jenna H. Burton, Christina Mazcko, Amy LeBlanc, Joseph M. Covey, Jiuping Ji, Robert J. Kinders, Ralph E. Parchment, Chand Khanna, Melissa Paoloni, Sue Lana, Kristen Weishaar, Cheryl London, William Kisseberth, Erika Krick, David Vail, Michael Childress, Jeffrey N. Bryan, Lisa Barber, E.J. Ehrhart, Michael Kent, Timothy Fan, Kelvin Kow, Nicole Northup, Heather Wilson-Robles, Joseph Tomaszewski, Julianne L. Holleran, Miguel Muzzio, Julie Eiseman, Jan H. Beumer, James H. Doroshow, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5830–5840.
https://doi.org/10.1158/1078-0432.CCR-18-1498
Published: 03 December 2018
View article titled, NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
Open the PDF for NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma in another window
Includes: Supplementary data
Journal Articles

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

George Somlo, Paul H. Frankel, Banu K. Arun, Cynthia X. Ma, Agustin A. Garcia, Tessa Cigler, Leah V. Cream, Harold A. Harvey, Joseph A. Sparano, Rita Nanda, Helen K. Chew, Timothy J. Moynihan, Linda T. Vahdat, Matthew P. Goetz, Jan H. Beumer, Arti Hurria, Joanne Mortimer, Richard Piekarz, Sharon Sand, Josef Herzog, Lily R. Van Tongeren, Katherine V. Ferry-Galow, Alice P. Chen, Christopher Ruel, Edward M. Newman, David R. Gandara, Jeffrey N. Weitzel
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4066–4076.
https://doi.org/10.1158/1078-0432.CCR-16-2714
Published: 01 August 2017
View article titled, Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <em>BRCA1</em>- or <em>BRCA2</em>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
Open the PDF for Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <em>BRCA1</em>- or <em>BRCA2</em>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083 in another window
Includes: Supplementary data
Journal Articles

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

Jacob D. Soumerai, Andrew D. Zelenetz, Craig H. Moskowitz, M. Lia Palomba, Paul A. Hamlin, Jr, Ariela Noy, David J. Straus, Alison J. Moskowitz, Anas Younes, Matthew J. Matasar, Steven M. Horwitz, Carol S. Portlock, Jason A. Konner, Mrinal M. Gounder, David M. Hyman, Martin H. Voss, Matthew G. Fury, Devika Gajria, Richard D. Carvajal, Alan L. Ho, Jan H. Beumer, Brian Kiesel, Zhigang Zhang, Alice Chen, Richard F. Little, Christine Jarjies, Thu O. Dang, Fallon France, Nishant Mishra, John F. Gerecitano
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4119–4126.
https://doi.org/10.1158/1078-0432.CCR-16-3068
Published: 01 August 2017
View article titled, The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Open the PDF for The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

Ivana Gojo, Jan H. Beumer, Keith W. Pratz, Michael A. McDevitt, Maria R. Baer, Amanda L. Blackford, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Mark J. Levis, Amy E. Dezern, Douglas E. Gladstone, Jiuping Jay Ji, Lihua Wang, Robert J. Kinders, Marie Pouquet, Ismail Ali-Walbi, Michelle A. Rudek, Weijie Poh, James G. Herman, Larry M. Karnitz, Scott H. Kaufmann, Alice Chen, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (3): 697–706.
https://doi.org/10.1158/1078-0432.CCR-16-0984
Published: 31 January 2017
View article titled, A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Open the PDF for A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer

Eve T. Rodler, Brenda F. Kurland, Melissa Griffin, Julie R. Gralow, Peggy Porter, Rosa F. Yeh, Vijayakrishna K. Gadi, Jamie Guenthoer, Jan H. Beumer, Larissa Korde, Sandra Strychor, Brian F. Kiesel, Hannah M. Linden, John A. Thompson, Elizabeth Swisher, Xiaoyu Chai, Stacie Shepherd, Vincent Giranda, Jennifer M. Specht
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2855–2864.
https://doi.org/10.1158/1078-0432.CCR-15-2137
Published: 14 June 2016
View article titled, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or <em>BRCA</em> Mutation–Associated Breast Cancer
Open the PDF for Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or <em>BRCA</em> Mutation–Associated Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent

Leonard J. Appleman, Sanjeeve Balasubramaniam, Robert A. Parise, Christine Bryla, Christophe E. Redon, Asako J. Nakamura, William M. Bonner, John J. Wright, Richard Piekarz, David R. Kohler, Yixing Jiang, Chandra P. Belani, Julie Eiseman, Edward Chu, Jan H. Beumer, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 721–729.
https://doi.org/10.1158/1078-0432.CCR-14-1333
Published: 16 February 2015
View article titled, A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent
Open the PDF for A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent in another window
Includes: Supplementary data
Journal Articles

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

Fan Lin, Mark C. de Gooijer, Eloy Moreno Roig, Levi C.M. Buil, Susan M. Christner, Jan H. Beumer, Thomas Würdinger, Jos H. Beijnen, Olaf van Tellingen
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (10): 2703–2713.
https://doi.org/10.1158/1078-0432.CCR-14-0084
Published: 14 May 2014
View article titled, ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
Open the PDF for ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy in another window
Includes: Supplementary data
Journal Articles

Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia

Ivana Gojo, Ming Tan, Hong-Bin Fang, Mariola Sadowska, Rena Lapidus, Maria R. Baer, France Carrier, Jan H. Beumer, Bean N. Anyang, Rakesh K. Srivastava, Igor Espinoza-Delgado, Douglas D. Ross
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1838–1851.
https://doi.org/10.1158/1078-0432.CCR-12-3165
Published: 02 April 2013
View article titled, Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia
Open the PDF for Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Shivaani Kummar, Jiuping Ji, Robert Morgan, Heinz-Josef Lenz, Shannon L. Puhalla, Chandra P. Belani, David R. Gandara, Deborah Allen, Brian Kiesel, Jan H. Beumer, Edward M. Newman, Larry Rubinstein, Alice Chen, Yiping Zhang, Lihua Wang, Robert J. Kinders, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1726–1734.
https://doi.org/10.1158/1078-0432.CCR-11-2821
Published: 14 March 2012
View article titled, A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Open the PDF for A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine

Jan H. Beumer, Julie L. Eiseman, Robert A. Parise, Erin Joseph, Joseph M. Covey, Merrill J. Egorin
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3529–3535.
https://doi.org/10.1158/1078-0432.CCR-07-4885
Published: 02 June 2008
View article titled, Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine
Open the PDF for Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine in another window
Journal Articles

Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2′-Deoxycytidine in Mice

Jan H. Beumer, Julie L. Eiseman, Robert A. Parise, Erin Joseph, Julianne L. Holleran, Joseph M. Covey, Merrill J. Egorin
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (24): 7483–7491.
https://doi.org/10.1158/1078-0432.CCR-06-1250
Published: 22 December 2006
View article titled, Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2′-Deoxycytidine in Mice
Open the PDF for Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2′-Deoxycytidine in Mice in another window
Journal Articles

A Mass Balance and Disposition Study of the DNA Methyltransferase Inhibitor Zebularine (NSC 309132) and Three of Its Metabolites in Mice

Jan H. Beumer, Erin Joseph, Merrill J. Egorin, Robert S. Parker, David Z. D'argenio, Joseph M. Covey, Julie L. Eiseman
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5826–5833.
https://doi.org/10.1158/1078-0432.CCR-06-1234
Published: 04 October 2006
View article titled, A Mass Balance and Disposition Study of the DNA Methyltransferase Inhibitor Zebularine (NSC 309132) and Three of Its Metabolites in Mice
Open the PDF for A Mass Balance and Disposition Study of the DNA Methyltransferase Inhibitor Zebularine (NSC 309132) and Three of Its Metabolites in Mice in another window